Keyword: ViaCyte

The series D positions ViaCyte to generate phase 1/2 data on one candidate while working to get another back into the clinic.

CRISPR Therapeutics is partnering with ViaCyte to develop off-the-shelf, gene-edited stem cell therapies for diabetes in a deal worth up to $25 million.

ViaCyte picked up $10 million to fund the clinical development of its stem cell-derived treatment for patients who have Type 1 diabetes and are at risk of complications.

ViaCyte and W.L. Gore will develop a delivery device for cell therapies that will protect the cells from immune rejection.

The Cell and Gene Therapy Catapult has teamed up with the University of Aberdeen to found a Type I diabetes cell therapy startup.